^
BIOMARKER:

MSI-H/dMMR

i
Other names: MSI-H, Microsatellite instability - high, dMMR
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related biomarkers:
MSI-H/dMMR
Prostate Cancer
pembrolizumab
Sensitive
:
A2
Front Oncol - 1 week - (New C4)
MSI-H/dMMR
Solid Tumor
dostarlimab
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR
Solid Tumor
pembrolizumab
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR
Endometrial Cancer
dostarlimab
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR
Endometrial Cancer
pembrolizumab
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR
Colon Cancer
nivolumab + ipilimumab
Sensitive
:
A2
ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR
Gastrointestinal Cancer
dostarlimab
Sensitive
:
C1
ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR
Solid Tumor
durvalumab
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR
Colorectal Cancer
avelumab
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR
Small Intestinal Carcinoma
pembrolizumab
Sensitive
:
A1
MSI-H/dMMR
Colorectal Cancer
pembrolizumab
Sensitive
:
A1
MSI-H/dMMR
Colorectal Cancer
nivolumab + ipilimumab
Sensitive
:
A1
MSI-H/dMMR
Colorectal Cancer
nivolumab
Sensitive
:
A1
MSI-H/dMMR
Biliary Tract Cancer
pembrolizumab
Sensitive
:
A1
MSI-H/dMMR
Gastric Cancer
pembrolizumab
Sensitive
:
A1
MSI-H/dMMR
Solid Tumor
tislelizumab
Sensitive
:
A1
MSI-H/dMMR
Colorectal Cancer
tislelizumab
Sensitive
:
A1
MSI-H/dMMR
Peritoneal Cancer
pembrolizumab
Sensitive
:
A2
MSI-H/dMMR
Esophageal Cancer
dostarlimab
Sensitive
:
C1
MSI-H/dMMR
Colorectal Cancer
dostarlimab
Sensitive
:
A2
MSI-H/dMMR
Colon Cancer
CAPOX
Sensitive
:
A2
MSI-H/dMMR
Colon Cancer
FOLFOX
Sensitive
:
A2
MSI-H/dMMR
Fallopian Tube Cancer
pembrolizumab
Sensitive
:
A2
MSI-H/dMMR
Maxillary Sinus Carcinoma
pembrolizumab
Sensitive
:
A2
MSI-H/dMMR
Penile Cancer
pembrolizumab
Sensitive
:
A2
MSI-H/dMMR
Endometrial Cancer
pembrolizumab + lenvatinib
Sensitive
:
A2
MSI-H/dMMR
Small Intestinal Carcinoma
nivolumab
Sensitive
:
A2
MSI-H/dMMR
Small Intestinal Carcinoma
pembrolizumab + ipilimumab
Sensitive
:
A2
MSI-H/dMMR
Small Intestinal Carcinoma
nivolumab + ipilimumab
Sensitive
:
A2
MSI-H/dMMR
Ovarian Cancer
pembrolizumab
Sensitive
:
A2
MSI-H/dMMR
Germ Cell Tumors
pembrolizumab
Sensitive
:
A2
MSI-H/dMMR
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive
:
A2
MSI-H/dMMR
Colorectal Cancer
pembrolizumab + ipilimumab
Sensitive
:
A2
MSI-H/dMMR
Rectal Cancer
nivolumab
Sensitive
:
A2
MSI-H/dMMR
Neuroendocrine Tumor
pembrolizumab
Sensitive
:
A2
MSI-H/dMMR
Pancreatic Adenocarcinoma
pembrolizumab
Sensitive
:
A2
MSI-H/dMMR
Cervical Cancer
pembrolizumab
Sensitive
:
A2
MSI-H/dMMR
Chordoma
pembrolizumab
Sensitive
:
A2
MSI-H/dMMR
Ewing Sarcoma
pembrolizumab
Sensitive
:
A2
MSI-H/dMMR
Osteosarcoma
pembrolizumab
Sensitive
:
A2
MSI-H/dMMR
Breast Cancer
pembrolizumab
Sensitive
:
A2